NCT02263950 - A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Solid Tumours

Interventions

DRUG

Artemether

Artemether sublingual spray at 20mg per spray. Dose escalation study design as per protocol; in Phase 1, three dose levels will be given. The Phase 2 dose will be determined from the results of Phase 1. All patients will receive 4 cycles of dosing, 28 days per cycle.

Trial Locations (2)

GU2 7XX

NOT_YET_RECRUITING

The Royal Surrey County Hospital, Guildford

SE1 9RT

RECRUITING

Guy's and St Thomas NHS Foundation Trust, London